Saturday 17 October 2026
Export MPLT’s income statement to Excel — free account
MapLight Therapeutics, Inc.
MPLT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.6% and free cash flow fell 31.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.70
0.32
−3.99%
Follow MPLT
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
7.20 | 20.01 |
Net Debt/EBITDA |
1.30 | 1.79 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
1.02 | 0.86 |
Capex/Depreciation |
0.74 | 0.31 |
| 0.00% | (121.74%) | |
| 0.00% | (52.29%) | |
ROIC |
0.00% | (68.95%) |
Return on Tangible Assets |
(77.67%) | (52.06%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(108.10) | (15.97) |
Cash per Share |
147.78 | 35.15 |
Shareholders Equity per Share |
(263.01) | 52.80 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(263.01) | 52.80 |
Free Cash Flow |
(79.58) | (138.61) |
Working Capital |
98.68 | 308.44 |
Capital Expenditures |
(0.77) | (0.47) |
Net Current Asset Value |
92.88 | 303.53 |
| Other line items | ||
Quick Ratio |
6.83 | 18.80 |
Depreciation/Fixed assets |
(0.86) | (1.39) |
Cash ROIC |
93.81% | (18.16%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(107.06) | (15.91) |
Capex per Share |
(1.05) | (0.05) |
Average Payables |
— | 2.60 |
Average Assets |
— | 308.21 |
Average Common Equity |
— | 132.37 |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates